Tag: Chris Parry
-
![Chris Parry Updates us on What’s New at EG]()
Chris Parry Updates us on What’s New at EG
In this episode, Jody Vance catches up with Equity Guru’s founder and CEO Chris Parry to talk about EG’s latest changes and updates to content and team members. Tune In!
-
![First Glance with Jody Vance (Ep 67): Equity Guru Founder Chris Parry Updates us on What’s New at EG]()
First Glance with Jody Vance (Ep 67): Equity Guru Founder Chris Parry Updates us on What’s New at EG
In this episode, Jody Vance catches up with Equity Guru’s founder and CEO Chris Parry to talk about EG’s latest changes and updates to content and team members. Tune In!
-
![Equity.Guru starts a wrestling promotion]()
Equity.Guru starts a wrestling promotion
In this episode, Jody Vance catches up with Equity Guru’s founder and CEO Chris Parry to talk about the company’s latest updates and New Extreme Wrestling. Tune In!
-
![First glance with Jody Vance: Equity Guru CEO Chris Parry]()
First glance with Jody Vance: Equity Guru CEO Chris Parry
In this episode, Jody Vance catches up with Equity Guru’s founder and CEO Chris Parry to talk about the company’s latest updates and New Extreme Wrestling. Tune In!
-
![Medexus (MDP.V) by Mackie Research upgrades their target price by 42%]()
Medexus (MDP.V) by Mackie Research upgrades their target price by 42%
“Medicine is a science of uncertainty and an art of probability.” – William Osler I think it’s appropriate I start the article by saying that I get it, biotech is not an easy industry to understand. The jargon used by those writing about the industry often takes away from the ingenious business models of some…
-
![Aequus Pharma (AQS.V) update including Q1,2021 financial highlights]()
Aequus Pharma (AQS.V) update including Q1,2021 financial highlights
On May 31, 2021 Aequus Pharmaceuticals (AQS.V) reported financial results for Q1, 2021. Aequus is a $19 million pharmaceutical company focused on developing and commercializing high quality, differentiated products. AQS is building a Canadian commercial platform through its own development pipeline and through license-acquisition. On November 20, 2020 Equity Guru’s Chris Parry spoke with Aequus’…
-
![Aequus Pharma (AQS.V) launches Evolve Eyedrops to eye care professionals in Canada]()
Aequus Pharma (AQS.V) launches Evolve Eyedrops to eye care professionals in Canada
Aequus is a $24 million pharmaceutical company focused on developing and commercializing high quality, differentiated products.
-
![Isracann (IPOT.C) stock moves after Israel eye-balls legal rec weed]()
Isracann (IPOT.C) stock moves after Israel eye-balls legal rec weed
Five days ago, the embattled Israeli government announced “a road map to legalize cannabis within one year” creating a regulated market for adult-use marijuana.
-
![Aequus (AQS.V) gains a new medical device licence for $90 million Canadian Dry Eye Disease market]()
Aequus (AQS.V) gains a new medical device licence for $90 million Canadian Dry Eye Disease market
Currently in Canada, the dry eye market is estimated at over $9O million, which includes both prescription and over-the-counter products.
-
![Isracann’s (IPOT.C) export strategy just got a green light]()
Isracann’s (IPOT.C) export strategy just got a green light
October 14, 2020 Isracann announced that “the government of Israel has officially enacted the legislation for the export of medical cannabis, clearing the way for sales abroad that the government expects could generate more than 1 billion shekels ($273 million) in annual revenue.”
